Abstract

Intensified oxidative modification of proteins and increased concentration of advanced oxidation protein products (AOPPs) are confirmed by many experimental investigations in different pathological states, especially these with well-known participation of oxidative stress (OS) in etiopathogenesis but also these with not well recognized its role. Presented data indicate that AOPPs play a significant role in many disorders with chronic background, because of they reflect both intensification of OS and the degree of pathological changes connected with OS in these diseases. This review sets out the clinical and diagnostic aspects of AOPPs in these diseases such as: renal diseases with different etiology, cardiovascular diseases, as well as connected with metabolic disturbances – e.g. diabetes, atherosclerosis or metabolic syndrome. Moreover results of investigation about utility of AOPPs measurement, mainly in plasma/serum, in these diseases are presented. The review and evaluation of application of AOPPs as useful marker in diagnosis, prognosis and monitoring the course of these diseases were performed. This paper also describes the suggested mechanisms of their action which contribute to biochemical and clinic changes undergoing in the condition of increased OS. Diagnostic or prognostic utility of AOPPs are especially indicated in the course of diabetes and its complications (diabetic nephropahy) and cardiovascular diseases.

References

• 1. Atabek M., Keskin M., Yazici C., Kendrici M., Hatipoglu N., KokluE., Kurtoglu S.: Protein oxidation in obesity and insulin resistance.Eur. J. Pediatr., 2006; 165: 753-756
  Google Scholar
• 2. Barsotti A., Fabbi P., Fedele M., Garibaldi S., Balbi M., BezanteG.P., Risso D., Indiveri F., Ghigliotti G., Brunelli C.: Role of advancedoxidation protein products and thiol ratio in patients with acutecoronary syndromes. Clin. Biochem., 2011; 44: 605-611
  Google Scholar
• 3. Baskol M., Baskol G., Kocer D., Ozbakir O., Yucesoy M.: Advancedoxidation protein products a novel marker of oxidative stress in ulcerativecolitis. J. Clin. Gastroenterol., 2008; 42: 687-691
  Google Scholar
• 4. Boulanger E., Moranne O., Wautier M.P., Witko-Sarsat V.,Descamps-Latscha B., Kandoussi A., Grossin N., Wautier J.L.: Changesin glycation and oxidation markers in patients starting peritonealdialysis: a pilot study. Perit. Dial. Int., 2006; 26: 207-212
  Google Scholar
• 5. Cakatay U.: Protein oxidation parameters in type 2 diabetic patientswith good and poor glycaemic control. Diabetes Metab., 2005;31: 551-557
  Google Scholar
• 6. Camilla R., Suzuki H., Dapra V., Loiacono E., Peruzzi L., AmoreA., Ghiggeri G.M., Mazzucco G., Scolari F., Gharavi A.G., Appel G.B.,Troyanov S., Novak J., Julian B.A., Coppo R.: Oxidative stress and galactose-deficientIgA1 as markers of progression in IgA nephropathy.Clin. J. Am. Soc. Nephrol., 2011; 6: 1903-1911
  Google Scholar
• 7. Cao W., Xu J., Zhou Z.M., Wang G.B., Hou F.F., Nie J.: Advancedoxidation protein products activate intrarenal renin-angiotensinsystem via a CD36-mediated, redox-dependent pathway. Antioxid.Redox. Signal., 2013; 18: 19-35
  Google Scholar
• 8. Capeillere-Blandin C., Gausson V., Nguyen A.T., Descamps-LatschaB., Drueke T., Witko-Sarsat V.: Respective role of uraemic toxins andmyeloperoxidase in the uraemic state. Nephrol. Dial. Transplant.,2006; 21: 1555-1563
  Google Scholar
• 9. Codoner-Franch P., Tavarez-Alonso S., Murria-Estal R., Tortajada-GirbesM., Simo-Jorda R., Alonso-Iglesias E.: Elevated advancedoxidation protein products (AOPPs) indicate metabolic risk in severelyobese children. Nutr. Metab. Cardiovasc. Dis., 2012; 22: 237-243
  Google Scholar
• 10. Coskun C., Kural A., Doventas Y., Koldas M., Ozturk H., Inal B.B.,Gumus A.: Hemodialysis and protein oxidation products. Ann. N. Y.Acad. Sci., 2007; 1100: 404-408
  Google Scholar
• 11. Coughlan M.T., Thorburn D.R., Penfold S.A., Laskowski A.,Harcourt B.E., Sourris K.C., Tan A.L., Fukami K., Thallas-Bonke V.,Nawroth P.P., Brownlee M., Bierhaus A., Cooper M.E., Forbes J.M.:RAGE-induced cytosolic ROS promote mitochondrial superoxidegeneration in diabetes. J. Am. Soc. Nephrol., 2009; 20: 742-752
  Google Scholar
• 12. de Cal M., Silva S., Cruz D., Basso F., Corradi V., Lentini P., NalessoF., Dissegna D., Goepel V., Chiaramonte S., Ronco C.: Oxidative stressand ‘monocyte reprogramming’ after kidney transplant: a longitudinalstudy. Blood Purif., 2008; 26: 105-110
  Google Scholar
• 13. Deng Y.Q., Fu Y., Su X.P., Tang Z.Y.: Biologic effects of advancedoxidative protein products on the human gingival fibroblasts.Zhonghua Kou Qiang Yi Xue Za Zhi, 2009; 44: 270-273
  Google Scholar
• 14. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., NguyenA.T., Gausson V., Mothu N., Cardoso C., Noël L.H., Guérin A.P., LondonG.M., Jungers P.: Early prediction of IgA nephropathy progression:proteinuria and AOPP are strong prognostic markers. Kidney Int.,2004; 66: 1606-1612
  Google Scholar
• 15. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., NguyenA.T., Gausson V., Mothu N., London G.M., Jungers P.: Advanced oxidationprotein products as risk factors for atherosclerotic cardiovascularevents in nondiabetic predialysis patients. Am. J. KidneyDis., 2005; 45: 39-47
  Google Scholar
• 16. Drueke T., Witko-Sarsat V., Massy Z., Descamps-Latscha B., GuerinA.P., Marchais S.J., Gausson V., London G.M.: Iron therapy, advancedoxidation protein products, and carotid artery intima-media thicknessin end-stage renal disease. Circulation, 2002; 106: 2212-2217
  Google Scholar
• 17. Feng Y., Shen C., Ma G., Wang J., Chen Z., Dai Q., Zhi H., Yang C.,Fu Q., Shang G., Guan Y.: Prolonged pain to hospital time is associatedwith increased plasma advanced oxidation protein products and poorprognosis in patients with percutaneous coronary intervention forST-elevation myocardial infarction. Heart Vessels, 2010; 25: 374-378
  Google Scholar
• 18. Forbes J.M., Coughlan M.T., Cooper M.E.: Oxidative stress as a majorculprit in kidney disease in diabetes. Diabetes, 2008; 57: 1446-1454
  Google Scholar
• 19. Furuya R., Kumagai H., Odamaki M., Takahashi M., Miyaki A.,Hishida A.: Impact of residual renal function on plasma levels ofadvanced oxidation protein products and pentosidine in peritonealdialysis patients. Nephron Clin. Pract., 2009; 112: c255-c261
  Google Scholar
• 20. Gillotte K.L, Horkko S., Witztum J.L., Steinberg D.: Oxidized phospholipids,linked to apolipoprotein B of oxidized LDL, are ligandsfor macrophage scavenger receptors. J. Lipid Res., 2000; 41: 824-833
  Google Scholar
• 21. Gleisner A., Martinez L., Pino R., Rojas I.G., Martinez A., AsenjoS., Rudolph M.I.: Oxidative stress markers in plasma and urine ofprepubertal patients with type 1 diabetes mellitus. J. Pediatr. Endocrinol.Metab., 2006; 19: 995-1000
  Google Scholar
• 22. Goi G., Baquero-Herrera C., Licastro F., Dogliotti G., Corsi M.M.:Advanced oxidation protein products (AOPP) and high-sensitiveC-reactive protein (hs-CRP) in an ‘‘atheroma-free model’’: Down’ssyndrome. Int. J. Cardiol. 2006; 113: 427-429
  Google Scholar
• 23. Guo Z.J., Niu H.X., Hou F.F., Fu N., Nagai R., Lu X., Chen B.H., ShanY.X., Tian J.W., Nagaraj R.H., Xie D., Zhang X.: Advanced oxidationprotein products activate vascular endothelial cells via a RAGE-mediatedsignaling pathway. Antioxid. Redox Signal., 2008; 10: 1699-1712
  Google Scholar
• 24. Kalousova M., Skrha J., Zima T.: Advanced glycation endproductsand advanced oxidation protein products in patients withdiabetes mellitus. Physiol. Res., 2002; 51: 597-604
  Google Scholar
• 25. Kalousova M., Sulkova S., Fialova L., Soukupova J., Malbohan I.M.,Spacek P., Braun M., Mikulíkova L., Fortova M., Horejsi M., Tesar V.,Zima T.: Glycoxidation and inflammation in chronic haemodialysispatients. Nephrol. Dial. Transplant., 2003; 18: 2577-2581
  Google Scholar
• 26. Kalousova M., Zak A., Soukupova J., Stipek S., Malbohan I.M.,Zima T.: Advanced glycation and oxidation products in patients withatherosclerosis. Cas. Lek. Cesk., 2005; 144: 385-389
  Google Scholar
• 27. Kalousova M., Zima T., Tesar V., Dusilova-Sulkova S., Skrha J.:Advanced glycoxidation end products in chronic diseases-clinicalchemistry and genetic background. Mutat. Res., 2005; 579: 37-46
  Google Scholar
• 28. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., Ohno M.: Increasedlevel of advanced oxidation protein products in patientswith coronary artery disease. Atherosclerosis, 2002; 162: 221-225
  Google Scholar
• 29. Kassab A., Piwowar A.: Cell oxidant stress delivery and cell dysfunctiononset in type 2 diabetes. Biochimie, 2012; 94: 1837-1848
  Google Scholar
• 30. Kaya C., Erkan A.F., Cengiz S.D., Dunder I., Demirel O.E., BilgihanA.: Advanced oxidation protein products are increased in womenwith polycystic ovary syndrome: relationship with traditional andnontraditional cardiovascular risk factors in patients with polycysticovary syndrome. Fertil. Steril., 2009; 92: 1372-1377
  Google Scholar
• 31. Kayali R., Telci A., Cakatay U., Karaca C., Akcay T., Sivas A., AltugT.: Oxidative protein damage parameters in plasma in chronicexperimental diabetes in rats. Eur. J. Med. Res., 2003; 8: 307-312
  Google Scholar
• 32. Knapik-Kordecka M., Piwowar A., Warwas M.: Zaburzenia równowagioksydacyjno-antyoksydacyjnej a czynniki ryzyka miażdżycyi powikłania naczyniowe u chorych na cukrzycę typu 2. Wiad. Lek.,2007; 60: 329-334
  Google Scholar
• 33. Kocak H., Gumuslu S., Sahin E., Ceken K., Gocmen Y.A., YakupogluG., Ersoy F.F., Tuncer M.: Advanced oxidative protein products areindependently associated with endothelial function in peritonealdialysis patients. Nephrology (Carlton), 2009; 14: 273-280
  Google Scholar
• 34. Kocak H., Oner-Iyidogan Y., Gurdol E., Oner P., Suzme R., Esin D.,Issever H.: Advanced oxidation protein products in obese women: its relationto insulin resistance and resistin. Clin. Exp. Med., 2007; 7: 173-178
  Google Scholar
• 35. Kostolanska J., Jakus V., Barak L.: HbA1c and serum levels of advancedglycation and oxidation protein products in poorly and wellcontrolled children and adolescents with type 1 diabetes mellitus.J. Pediatr. Endocrinol. Metab., 2009; 22: 433-442
  Google Scholar
• 36. Kraśniak A., Dróżdż M., Pasowicz M., Chmiel G., Kowalczyk-MichałekM., Szumilak D., Podolec P., Klimeczek P., Konieczyńska M.,Wicher-Muniak E., Tracz W., Sułowicz W., Drueke T.: Wpływ mikrozapaleniai stresu oksydacyjnego na progresje miażdżycy i zwapnieńw układzie krążenia chorych hemodializowanych w okresie dwuletniejobserwacji. Przegl. Lek., 2007; 64: 140-147
  Google Scholar
• 37. Krzystek-Korpacka M., Patryn E., Boehm D., Berdowska I.,Zieliński B., Noczyńska A.: Advanced oxidation protein products(AOPPs) in juvenile overweight and obesity prior to and followingweight reduction. Clin. Biochem., 2008; 41: 943-949
  Google Scholar
• 38. Krzystek-Korpacka M., Salmonowicz B., Boehm D., Berdowska I.,Zieliński B., Patryn E., Noczyńska A., Gamian A.: Diagnostic potentialof oxidative stress markers in children and adolescent with type 1diabetes. Clin. Biochem., 2008; 41: 48-55
  Google Scholar
• 39. Kuchta A., Pacanis A., Kortas-Stempak B., Cwiklińska A., ZiętkiewiczM., Renke M., Rutkowski B.: Estimation of oxidative stress markers inchronic kidney disease. Kidney Blood Press. Res., 2011; 34: 12-19
  Google Scholar
• 40. Kuppusamy U.R., Indran M., Ahmad T., Wong S.W., Tan S.Y.,Mahmood A.A.: Comparison of oxidative damage in Malaysian endstagerenal disease patients with or without non-insulin-dependentdiabetes mellitus. Clin. Chim. Acta, 2005; 351: 197-201
  Google Scholar
• 41. Lentini P., de Cal M., Cruz D., Chronopoulos A., Soni S., NalessoF., Zanella M., Garzotto F., Brendolan A., Piccinni P., Ronco C.: Therole of advanced oxidation protein products in intensive care unitpatients with acute kidney injury. J. Crit. Care, 2010; 25: 605-609
  Google Scholar
• 42. Li H.Y., Hou F.F., Zhang X., Chen P.Y., Liu S.X., Feng J.X., Liu Z.Q.,Shan Y.X., Wang G.B., Zhou Z.M., Tian J.W., Xie D.: Advanced oxidationprotein products accelerate renal fibrosis in a remnant kidneymodel. J. Am. Soc. Nephrol., 2007; 18: 528-538
  Google Scholar

Full text